Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
deals
5
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
pfizer
5
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alzheimer's disease
biotech
startups
abbvie
bayer
biogen
cancer
cancer immunotherapy
celgene
eli lilly
gilead sciences
johnson & johnson
What
bio
drug
5
×
roundup
acquisitions
alzheimer’s
biggest
ceo
companies
nash
news
week
aducanumab
albert
amyloid
angst
approved
bagged
billions
biogen
biogen’s
bourla
brammer
build
buy
company
company’s
crispr
daniel
debut
different
digital
disease
dyne’s
effects
epidemic
fail
failure
fatty
fda
felt
Language
unknown
unset
Current search:
pfizer
×
drug
×
deals
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
